Lp(a) and PCSK9 inhibition in nominally controlled LDL-C patients
Watch the video and learn on how to leverage incremental clinical benefit to patients with recent ACS and LDL-C near 70 mg/dL from optimized statin therapy and PCSK9i.
![](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-kw/Article-Images/images/jcr_content-(33).jpg/jcr:content/jcr_content%20(33).jpg)
Related articles
MAT-BH-2200017/v2/Jun 2023